Vitamin K2 / cMyc Cancer Research Results

VitK2, Vitamin K2: Click to Expand ⟱
Features:
Vitamin K2 (menaquinone)
Menaquinone-4 (MK-4), a subtype of vitamin K2 Helps blood clot, calcium metabolise and heart health.
Bone health: Vitamin K2 helps to regulate calcium levels in the body, which can help to prevent conditions such as osteoporosis and fractures.
Vitamin K2 has been studied for its potential role in cancer prevention and treatment. Some of the key findings include:
-Shown to inhibit the growth of cancer cells, including those found in leukemia, lung cancer, and prostate cancer.
-Shown to induce apoptosis (cell death) in cancer cells, which can help to prevent the spread of cancer.
-Shown to have anti-angiogenic effects, which means it can help to prevent the formation of new blood vessels that feed cancer cells.
-Synergistic effects with other nutrients, such as vitamin D and calcium, to enhance its anti-cancer effects.

UBIAD1 is the enzyme that makes MK-4 inside tissues

Vitamin K2 exists in several forms known as menaquinones, with MK-4 and MK-7 being the most studied. MK-4 is often used in Japan for therapeutic purposes, whereas MK-7 (derived from bacterial fermentation) is widely available as a supplement in Western countries.
For bone and cardiovascular health—and by extension, exploring potential anticancer benefits—doses for MK-7 commonly range from 90 to 200 micrograms per day.
cMyc, cellular-MYC oncogene: Click to Expand ⟱
Source:
Type: oncogene
The MYC proto-oncogenes are among the most commonly activated proteins in human cancer. The oncogene c-myc, which is frequently over-expressed in cancer cells, is involved in the transactivation of most of the glycolytic enzymes including lactate dehydrogenase A (LDHA) and the glucose transporter GLUT1 [51,52]. Thus, c-myc activation is a likely candidate to promote the enhanced glucose uptake and lactate release in the proliferating cancer cell. The c-Myc oncogene is a ‘master regulator’ of both cellular growth and metabolism in transformed cells.
-C-myc is a common oncogene that enhances aerobic glycolysis in the cancer cells by transcriptionally activating GLUT1, HK2, PKM2 and LDH-A

Inhibitors (downregulate):
Curcumin
Resveratrol: downregulate c-Myc expression.
Epigallocatechin Gallate (EGCG)
Quercetin
Berberine: decrease c-Myc expression and repress its transcriptional activity.
Scientific Papers found: Click to Expand⟱
1214- VitK2,    Vitamin K2 promotes PI3K/AKT/HIF-1α-mediated glycolysis that leads to AMPK-dependent autophagic cell death in bladder cancer cells
- in-vitro, Bladder, T24/HTB-9 - in-vitro, Bladder, J82
Glycolysis↑, GlucoseCon↑, lactateProd↑, TCA↓, PI3K↑, Akt↑, AMPK↑, mTORC1↓, TumAuto↑, GLUT1↑, HK2↑, LDHA↑, ACC↓, PDH↓, eff↓, cMyc↓, Hif1a↑, p‑Akt↑, eff↓, eff↓, eff↓, eff↓, ROS↑,
1817- VitK2,    Research progress on the anticancer effects of vitamin K2
- Review, Var, NA
TumCCA↑, Apoptosis↑, TumAuto↑, TumCI↓, TumCG↓, ChemoSen↓, ChemoSideEff↓, toxicity∅, eff↑, cycD1/CCND1↓, CDK4↓, eff↑, IKKα↓, NF-kB↓, other↑, p27↑, cMyc↓, i-ROS↑, Bcl-2↓, BAX↑, p38↑, MMP↓, Casp9↑, p‑ERK↓, RAS↓, MAPK↓, p‑P53↑, Casp8↑, Casp3↑, cJun↑, MMPs↓, eff↑, eff↑,

Showing Research Papers: 1 to 2 of 2

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 2

Pathway results for Effect on Cancer / Diseased Cells:


Redox & Oxidative Stress ⓘ

ROS↑, 1,   i-ROS↑, 1,  

Mitochondria & Bioenergetics ⓘ

MMP↓, 1,  

Core Metabolism/Glycolysis ⓘ

ACC↓, 1,   AMPK↑, 1,   cMyc↓, 2,   GlucoseCon↑, 1,   Glycolysis↑, 1,   HK2↑, 1,   lactateProd↑, 1,   LDHA↑, 1,   PDH↓, 1,   TCA↓, 1,  

Cell Death ⓘ

Akt↑, 1,   p‑Akt↑, 1,   Apoptosis↑, 1,   BAX↑, 1,   Bcl-2↓, 1,   Casp3↑, 1,   Casp8↑, 1,   Casp9↑, 1,   MAPK↓, 1,   p27↑, 1,   p38↑, 1,  

Transcription & Epigenetics ⓘ

cJun↑, 1,   other↑, 1,  

Autophagy & Lysosomes ⓘ

TumAuto↑, 2,  

DNA Damage & Repair ⓘ

p‑P53↑, 1,  

Cell Cycle & Senescence ⓘ

CDK4↓, 1,   cycD1/CCND1↓, 1,   TumCCA↑, 1,  

Proliferation, Differentiation & Cell State ⓘ

p‑ERK↓, 1,   mTORC1↓, 1,   PI3K↑, 1,   RAS↓, 1,   TumCG↓, 1,  

Migration ⓘ

MMPs↓, 1,   TumCI↓, 1,  

Angiogenesis & Vasculature ⓘ

Hif1a↑, 1,  

Barriers & Transport ⓘ

GLUT1↑, 1,  

Immune & Inflammatory Signaling ⓘ

IKKα↓, 1,   NF-kB↓, 1,  

Drug Metabolism & Resistance ⓘ

ChemoSen↓, 1,   eff↓, 5,   eff↑, 4,  

Functional Outcomes ⓘ

ChemoSideEff↓, 1,   toxicity∅, 1,  
Total Targets: 47

Pathway results for Effect on Normal Cells:


Total Targets: 0

Scientific Paper Hit Count for: cMyc, cellular-MYC oncogene
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:168  Target#:35  State#:%  Dir#:1
  wNotes=0  sortOrder:rid,rpid

 

Home Page